Biotech & MedTech News
-
DIAGNOS is filing for the Saudi FDA Authorization of Its CARA SYSTEM, an AI Assisted Medical Device
March 12, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
Voyageur Pharmaceuticals Advances Frances Creek Project, Paving the Way for a Secure, Vertically Integrated Barium Contrast Product Line
March 4, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”) is pleased to…
-
Voyageur Clarifies Terms of Previously Announced Agreement
March 3, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) (“Voyageur” or the “Company”) wishes…
-
DIAGNOS Announces Amendment to Convertible Debentures
February 28, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
DIAGNOS to File for FDA Pre-Market Authorization of Its AI-Powered CARA SYSTEM and Engages Ora as Regulatory Specialist
February 25, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
DIAGNOS to Present at Centurion One Capital 8th Annual Toronto Growth Conference
February 24, 2025 (Source) — Diagnos Inc. (TSXV: ADK) (OTCQB: DGNOF) (FSE: 4D4A) (“DIAGNOS” or the “Corporation”), a pioneer…
-
Voyageur Pharmaceuticals Grants Deferred Share Units
February 24, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) (“Voyageur” or the “Corporation”), a provider of innovative…
-
Voyageur Advances MRI Drug Development Using Next Generation Endohedral Fullerenes
February 18, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”) is pleased to…
-
Voyageur Receives $600K Grant from Alberta Innovates for Product Development
Voyageur receives $600,000 in funding through Alberta Innovates AICE-Market Access Program February 5, 2025 (Source) — Voyageur Pharmaceuticals…
-
DIAGNOS Announces Closing of Private Placement
February 5, 2025 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
